From Clinical Trials to Clinical Implications: PARP Inhibitor Combinations in Advanced Prostate Cancer

Access Activity

Overview / Abstract:

Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with high disease burden and poor outcomes despite androgen deprivation therapy. This activity by Neeraj Agarwal, MD, provides strategies for germline genetic testing and somatic testing to best inform treatment. Poly (ADP-ribose) polymerase (PARP) inhibitor therapy provides a unique approach to treatment. Dr. Agarwal reviews safety and efficacy findings from recent clinical trials for the two PARP inhibitors, olaparib and rucaparib, approved in the United States for mCRPC. He also shares observations regarding PARP inhibitors in combination with other therapies.

Expiration

Jun 15, 2022

Discipline(s)

Physician CME

Format

Webinar / Webcast / Video

Credits / Hours

0.5 AMA PRA Category 1 Credit™.

Accreditation

ACCME

Presenters / Authors / Faculty

FACULTY REVIEWER
Neeraj Agarwal, MD
Professor of Medicine
Presidential Endowed Chair of Cancer Research
Co-leader, Experimental Therapeutics Program
Director, GU Medical Oncology
Huntsman Cancer Institute
University of Utah
Salt Lake City, Utah

Activity Specialities / Related Topics

Oncology / Cancer / Radiation Therapy

Sponsors / Supporters / Grant Providers

This educational activity is supported by educational grants from AstraZeneca and Merck & Co., Inc.

Keywords / Search Terms

Annenberg Center for Health Sciences at Eisenhower Prostate Cancer • PARP inhibitor mechanism of action • Olaparib clinical trials • Rucaparib clinical trials • PARP inhibitor combination therapy Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map